VANCOUVER, BC -- (MARKET WIRE) -- April 02, 2007 -- Upstream Biosciences Inc. (OTCBB: UPBS) (“Upstream” or “the Company”), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has appointed NimbleGen Systems, Inc. to provide Upstream with laboratory services using NimbleGen’s whole genome chromatin immunoprecipitation (ChIP)-chip arrays and laboratory services to validate Upstream’s in silico binding site predictions, which marks the commencement of an important phase of our biomarker validation process.
